Reporting Incidences of Neuroblastoma in Various Resource Settings.
Journal
JCO global oncology
ISSN: 2687-8941
Titre abrégé: JCO Glob Oncol
Pays: United States
ID NLM: 101760170
Informations de publication
Date de publication:
06 2021
06 2021
Historique:
entrez:
17
6
2021
pubmed:
18
6
2021
medline:
6
8
2021
Statut:
ppublish
Résumé
The incidences of neuroblastoma (NB) differ significantly between various resource settings because of varying quality of cancer registries and underdiagnoses. This study aimed to evaluate current regional variations as reported by international cancer registries and the theoretical and reported differences in international NB incidences and to evaluate South Africa (SA) as a case for variable reporting. A comprehensive literature review on registries reporting on NB was performed to construct incidence tables. The SEER Program incidence of 10.5/million children was used to calculate the expected number of NB cases for each country. Registry data of NB cases between 2000 and 2016 were requested from The South African National Cancer registry (SA-NCR) and the South African Children's Tumour Registry (SACTR) for comparison and to perform a probabilistic linkage study. Internationally, incidences varied between -97.1% and +80% compared with the SEER program. SA under-reported NB cases by an estimated 74.2%. Between 2000 and 2016, the SA-NCR reported between 23 and 51 cases/year, whereas the SACTR reported between 18 and 57 cases/year for the same period. The incidence reported by the SA-NCR varied between 1.5 and 2.8/million children under 15-year per year, whereas the SACTR reported 1.74-2.6 cases/million children. Both registries reported incidences less than high-income country. A probabilistic record linkage of the two registries resulted in a combined incidence of 2.9 cases/million children. As with most low- and middle-income countries, SA has either a lower incidence or underdiagnoses of NB cases. The reasons for under-reporting are not clear, but can be due to undiagnosed NB cases with spontaneous regression, missed possible cases because of lack of autopsies, and diagnosed cases not recorded in registries.
Identifiants
pubmed: 34138644
doi: 10.1200/GO.21.00054
pmc: PMC8457875
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
947-964Références
Curr Opin Pediatr. 2013 Feb;25(1):3-15
pubmed: 23295716
J Clin Oncol. 1998 Apr;16(4):1265-9
pubmed: 9552024
Cancer Epidemiol. 2015 Feb;39(1):21-8
pubmed: 25599927
West Indian Med J. 2010 Oct;59(5):465-8
pubmed: 21473390
Lancet Oncol. 2015 Aug;16(8):e414-21
pubmed: 26248849
JCO Glob Oncol. 2020 Aug;6:1264-1275
pubmed: 32762563
S Afr Med J. 2015 Jan 12;105(2):107-9
pubmed: 26242527
Pediatr Blood Cancer. 2014 Apr;61(4):587-92
pubmed: 24214130
Pediatr Blood Cancer. 2017 Sep;64(9):
pubmed: 28164435
Lancet Oncol. 2019 Apr;20(4):483-493
pubmed: 30824204
Forensic Sci Med Pathol. 2011 Mar;7(1):47-52
pubmed: 20857235
S Afr Med J. 2015 Nov;105(11):939-47
pubmed: 26632323
Cancer Epidemiol. 2013 Dec;37(6):803-6
pubmed: 24211152
Expert Rev Anticancer Ther. 2017 Apr;17(4):369-386
pubmed: 28142287
J Clin Oncol. 2008 Mar 20;26(9):1504-10
pubmed: 18349403
Ecancermedicalscience. 2017 Jul 28;11:755
pubmed: 28900468
Lancet Oncol. 2017 Jun;18(6):719-731
pubmed: 28410997
Lancet Oncol. 2019 Sep;20(9):e493-e502
pubmed: 31395474
J Glob Oncol. 2018 Jul;4:1-12
pubmed: 30096010
J Trop Pediatr. 2015 Jun;61(3):165-73
pubmed: 25724211
Int J Cancer. 2018 May 15;142(10):1977-1985
pubmed: 29250786
J Glob Oncol. 2016 Mar 2;2(4):169-173
pubmed: 28717698
Arch Pathol Lab Med. 2006 Dec;130(12):1780-5
pubmed: 17149950
Oncotarget. 2017 Mar 14;8(11):18444-18455
pubmed: 28055978
Br J Cancer. 2009 Mar 10;100(5):853-7
pubmed: 19223904
Health Aff (Millwood). 2017 Nov;36(11):1866-1875
pubmed: 29137514
Trop Doct. 2017 Oct;47(4):370-374
pubmed: 28403698